The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence free interval (IBCRFI) in patients (pts) with positive axillary (PAx) nodes who are ypN0 after neoadjuvant chemotherapy (NC).
 
Eleftherios P. Mamounas
Honoraria - Genentech/Roche; Genomic Health
Consulting or Advisory Role - bioTheranostics; Celcuity; Celgene; Genomic Health; GRAIL; Macrogenics; Novartis; Pfizer; Ventana Medical Systems
Speakers' Bureau - Genentech/Roche; Genomic Health
Travel, Accommodations, Expenses - Celgene; Genentech/Roche; Genomic Health
 
Hanna Bandos
No Relationships to Disclose
 
Julia R. White
Honoraria - Qfix; Qfix
 
Thomas B. Julian
No Relationships to Disclose
 
Atif J. Khan
Consulting or Advisory Role - Elekta
Research Funding - Cianna Medical (Inst); Elekta (Inst)
 
Simona Flora Shaitelman
Consulting or Advisory Role - MD Anderson Physician’s Network
Research Funding - Elekta
 
Mylin Ann Torres
No Relationships to Disclose
 
Frank Vicini
Employment - 21st Century Oncology
Consulting or Advisory Role - ImpediMed
 
Patricia A. Ganz
Leadership - Intrinsic LifeSciences (I)
Stock and Other Ownership Interests - Abbott Laboratories; GlaxoSmithKline; Intrinsic LifeSciences (I); Johnson & Johnson; Merck; Merganser Biotech (I); Novartis; Pfizer; Silarus Therapeutics (I); Teva; xenon pharma (I)
Honoraria - Biogen (I)
Consulting or Advisory Role - InformedDNA; Keryx (I); Lilly; Merganser Biotech (I); Silarus Therapeutics (I); Vifor Pharma (I)
Research Funding - Keryx (I)
Patents, Royalties, Other Intellectual Property - related to iron metabolism and the anemia of chronic disease (I); Up-to-Date royalties for section editor on survivorship
Travel, Accommodations, Expenses - Intrinsic LifeSciences (I); Keryx (I)
 
Susan Ann McCloskey
No Relationships to Disclose
 
Soonmyung Paik
No Relationships to Disclose
 
Nilendu Gupta
No Relationships to Disclose
 
X. Allen Li
No Relationships to Disclose
 
Dominic J. DiCostanzo
No Relationships to Disclose
 
Walter John Curran
Stock and Other Ownership Interests - Nanthealth
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb
Consulting or Advisory Role - eviti
Research Funding - Abbvie (Inst)
 
Norman Wolmark
Research Funding - Bayer (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Abbvie; Genentech; GHI Pharma